We al are very familiar with the significant problem in the treatment of prostate cancer, even therapies that initially work stop working and our disease continues to progress. The inevitable onset of this resistance to treatment with antiandrogens (ADT) such as Lupron or Zoladex is not limited just to this class of drugs. We have [...]
It is fairly common practice for those diagnosed with breast cancer to have genetic testing. Genetic testing is almost unheard of when men are diagnosed with prostate cancer. Current research shows that genetic testing for men with prostate cancer could provide important information about both potential treatment efficacy and prognosis. A recent look at the [...]
According to a report released recently by the UK charity Macmillan Cancer Support exercise can benefit cancer survivors, including prostate cancer survivors. This report disproves the theory that those suffering with cancer or who have beaten the disease should simply rest. Rest no more, exercise should be prescribed to those at all stages of cancer [...]
The use of Ketoconazole (Keto) in men with advanced prostate cancer is not considered mainstream, however there is clear evidence that it does reduce PSA in men with castrate resistant prostate cancer. Currently, most men with advanced prostate cancer who do use Keto utilize it prior to chemotherapy. There has been little literature evaluating the [...]
According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]
There is a constant debate between both oncologist and advocates about the value and safety of 5-alpha-reductase inhibitors (Proscar and Avodart) both in the early treatment and later treatment of men with prostate cancer. In fact, I have had an on-going private debate with one very knowledgeable educator advocate over this issue. I often have [...]
Data from the recent ASCO conference on a phase II study of cabozantinib (XL184) in patients with advanced solid tumors, including prostate cancer, demonstrates that the investigational treatment has activity in both bone and soft tissue. This study evaluated the efficacy and safety of cabozantinib compared to placebo in 9 different solid tumor types including [...]
From Anthony Hardie, Madison, Wis. All: I've just gone through the full Defense Committee bill (before yesterday's markup) and the corresponding report language on the various CDMRP programs. The results are below. FY12 Defense Appropriations -- Full Committee Bill (before yesterday's markup): 1. Several programs would not be funded at all: most notably the sort [...]
Researchers from the Mayo Clinic recently announced results at the American Urological Association (AUA) Annual Meeting from a long-term study that indicates that surgery can improve life expectancy for men with advanced prostate cancer. Their study shows that 80% of men who have advanced prostate cancer and still choose to have surgery survive for at [...]
Currently the American Urologic Association is holding their annual conference. Like the ASCO and AACR conferences there are many presentations and posters given that harkens the latest in research findings for general urological topics as well as for prostate cancer. I will be reporting on a number of these findings over the next period of [...]
